AdaptHealth Corp. Investigation - AHCO

Company
AdaptHealth Corp. (NASDAQ: AHCO)

Learn more about the AdaptHealth Corp. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

AdaptHealth Corp. Investigation Details

AdaptHealth Corp. shares fell as much as 26% after the Company reported second quarter revenue of $740.3 million, well below approximately $847 million expected, a GAAP loss driven in part by a $144.2 million goodwill impairment charge, and a substantial reduction to full-year guidance. Adjusted EBITDA came in at $132 million for the quarter, against roughly $160 million expected. Alongside those results, AdaptHealth reset its 2026 continuing-operations outlook to approximately $2.85 billion to $2.89 billion in revenue and $490 million to $520 million in adjusted EBITDA. Management attributed the reset to the Diabetes Health divestiture, a capitated contract, manufacturer pricing, and other portfolio actions. The investigation concerns the scale of that exposure. The reduced revenue range represents a decline of roughly 16% to 19% from the guidance figures the Company had carried weeks earlier.

Get Started